Shopping Cart

Remove All
Your shopping cart is currently empty

Cell Cycle/Checkpoint

Nucleoside Antimetabolite/Analog

Poly(ADP-ribose) Glycohydrolase (PARG)

Serine/threonin kinase

PLK

Polo-like kinase (PLK) is a highly conserved serine/threonine protein kinase with a highly homologous serine/threonine kinase domain at its N-terminus, which regulates PLK activity and subcellular dynamics at the C-terminus and targeted polo-box domain (PBD). There are many PLK family members, and there are four subtypes in the human body, namely PLK1, PLK2, PLK3, and PLK4, which play important roles in the regulation of various phases of the cell cycle.

Filter HomeSignaling PathwaysCell Cycle/CheckpointPLK

Wortmannin

T628319545-26-7

Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8 48 nM) that blocks autophagy.

In Stock

Size

QTY

Onvansertib

T62471034616-18-6

Onvansertib (NMS-1286937) is a PLK1 inhibitor (IC50=2 nM) with high selectivity and oral activity. Onvansertib has antitumor activity and inhibits tumor growth.

In Stock

Size

QTY

Pyridoxine

T097365-23-6

Pyridoxine (Vitamin B6) is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading.

In Stock

Size

QTY

BI 2536

T6173755038-02-9

BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.

In Stock

Size

QTY

(E/Z)-Rigosertib sodium

T60701225497-78-8

ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells.It is a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity.

In Stock

Size

QTY

Volasertib

T6019755038-65-4

Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2 PLK3 (IC50s: 5 56 nM).

In Stock

Size

QTY

Dihydrobaicalein

TN384835683-17-1

Dihydrobaicalein is a natural product from Scutellaria baicalensis, a PLK1 inhibitor (IC50:6.3 μM).Dihydrobaicalein inhibits VRK2 and PLK2.

$195

In Stock

Size

QTY

Poloxin-2

T25969321695-37-8In house

Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.

$350

In Stock

Size

QTY

Plogosertib

T713991137212-79-3In house

Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors. and hematologic tumors.

$228

In Stock

Size

QTY

Rigosertib

T16750592542-59-1

Rigosertib (ON-01910) is a selective, non-ATP-competitive PLK1 inhibitor (IC50: 9 nM) and multi-kinase inhibitor. As a selective anti-cancer agent, Rigosertib induces apoptosis by inhibiting the PI3 kinase Akt pathway, promotes histone H2AX phosphorylation, and induces G2 M arrest in the cell cycle.

In Stock

Size

QTY

HMN-214

T2438173529-46-9

HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.

In Stock

Size

QTY

GSK461364

T6282929095-18-1

GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2 3.

In Stock

Size

QTY

ocifisertib(cfi-400945 free base)

T73841338806-73-7

Ocifisertib (CFI-400945 free base) is a potent, selective and orally active inhibitor of polo-like kinase 4 (PLK4; Ki value 0.26 nM; IC50 value 2.8 nM).

In Stock

Size

QTY

mps1-in-2

T18391228817-38-6

Mps1-IN-2 is a potent, selective, and ATP-competitive inhibitor of both Mps1 and Plk1.

In Stock

Size

QTY

3mb-pp1

T21678956025-83-5In house

3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.

In Stock

Size

QTY

MLN0905

T27041228960-69-7

MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).

In Stock

Size

QTY

Centrinone

T149271798871-30-3

Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).

In Stock

Size

QTY

(Z)-LFM-A13

T6217244240-24-2

(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.

In Stock

Size

QTY

Cyclapolin 9

T2270040533-25-3

Cyclapolin 9 is a selective, potent, and ATP-competitive inhibitor of polo-like kinase 1 (PLK1) with an IC50 of 500 nM, and has not shown activity against other kinases.

In Stock

Size

QTY

SBE13 Hydrochloride

T22711052532-15-6

SBE13 Hydrochloride (SBE 13 HCl) is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2 3.

In Stock

Size

QTY

tak-960

T72001137868-52-0

TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.

In Stock

Size

QTY

AAPK-25

T102152247919-28-2

AAPK-25 is a potent and selective Aurora PLK dual inhibitor with anti-tumor activity, causing mitotic delay and arresting cells in prometaphase, followed by increased apoptosis. It targets Aurora-A -B -C with Kd values ranging from 23-289 nM.

In Stock

Size

QTY